Humacyte, Inc. Total Liabilities and Equity
Humacyte, Inc. (HUMA) had Total Liabilities and Equity of $138.09 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-12
- 2026-06-30: Liabilities and Equity $138.09M.
- 2026-03-31: Liabilities and Equity $110.56M.
- 2025-12-31: Liabilities and Equity $116.37M.
- 2025-09-30: Liabilities and Equity $91.51M.
| Period end | Liabilities and Equity | Liabilities and Equity as first filed |
|---|---|---|
| 2026-06-30 | $138.09M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $110.56M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $116.37M 10-Q · filed 2026-08-12 | |
| 2025-09-30 | $91.51M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $138.79M 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $162.55M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $137.87M 10-K · filed 2026-03-27 | |
| 2024-09-30 | $114.76M 10-Q · filed 2024-11-08 | |
| 2024-06-30 | $138.28M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $161.47M 10-Q · filed 2024-05-13 | |
| 2023-12-31 | $128.22M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $149.38M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $168.11M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $182.98M 10-Q · filed 2023-05-12 | |
| 2022-12-31 | $204.30M 10-K · filed 2024-03-28 | |
| 2022-09-30 | $226.22M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $246.37M 10-Q · filed 2022-08-12 | |
| 2022-03-31 | $264.47M 10-Q · filed 2022-05-13 | |
| 2021-12-31 | $286.53M 10-K · filed 2023-03-24 | |
| 2021-09-30 | $303.36M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $100.51M 10-Q · filed 2021-08-16 | |
| 2021-03-31 | $100.67M 10-Q · filed 2021-05-17 | |
| 2020-12-31 | $106.69M 10-K · filed 2022-03-29 | $101.26M 10-K · filed 2021-02-16 |
| 2020-09-30 | $101.32M 10-Q · filed 2020-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |